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Strengths and limitations of this study
 ► This article draws together a variety of sources of 
information to demonstrate significant differences 
in the global warming potential of different inhalers.
 ► The National Health Service digital database provid-
ed a large, reliable dataset for us to analyse cost and 
greenhouse gas release in various scenarios.
 ► We calculated cost and greenhouse gas emissions 
for various scenarios in which inhalers are changed, 
and for different classes of inhalers (eg, inhaled ste-
roids, beta- agonists).
 ► We were unable to analyse national prescription 
data by diagnosis and do not know which of the 
inhalers might have been used for asthma, chronic 
obstructive pulmonary disease or other diagnoses.
 ► Detailed information about the carbon footprint of all 
inhalers is not publicly available.
AbStrACt
Objectives Metered- dose inhalers (MDIs) contain 
propellants which are potent greenhouse gases. Many 
agencies propose a switch to alternative, low global 
warming potential (GWP) inhalers, such as dry powder 
inhalers (DPIs). We aimed to analyse the impact on 
greenhouse gas emissions and drug costs of making this 
switch.
Setting We studied National Health Service prescription 
data from England in 2017 and collated carbon footprint 
data on inhalers commonly used in England.
Design Inhalers were separated into different categories 
according to their mechanisms of action (eg, short- acting 
beta- agonist). Within each category we identified low and 
high GWP inhalers and calculated the cost and carbon 
impact of changing to low GWP inhalers. We modelled 
scenarios for swapping proportionally according to the 
current market share of each equivalent DPI (model 1) and 
switching to the lowest cost pharmaceutically equivalent 
DPI (model 2). We also reviewed available data on the 
carbon footprint of inhalers from scientific publications, 
independently certified reports and patents to provide 
more accurate carbon footprint information on different 
types of inhalers.
results If MDIs using HFA propellant are replaced with 
the cheapest equivalent DPI, then for every 10% of MDIs 
changed to DPIs, drug costs decrease by £8.2M annually. 
However if the brands of DPIs stay the same as 2017 
prescribing patterns, for every 10% of MDIs changed 
to DPIs, drug costs increase by £12.7M annually. Most 
potential savings are due to less expensive long- acting 
beta- agonist (LABA)/inhaled corticosteroids (ICS) inhalers. 
Some reliever inhalers (eg, Ventolin) have a carbon footprint 
over 25 kg CO2e per inhaler, while others use far less 
1,1,1,2- tetrafluoroethane (HFA134a) (eg, Salamol) with a 
carbon footprint of <10 kg CO2e per inhaler. 1,1,1,2,3,3,
3- Heptafluoropropane (HFA227ea) LABA/ICS inhalers (eg, 
Flutiform) have a carbon footprint over 36 kg CO2e, compared 
with an equivalent HFA134a combination inhaler (eg, Fostair) 
at <20 kg CO2e. For every 10% of MDIs changed to DPIs, 58 
kt CO2e could be saved annually in England.
Conclusions Switching to DPIs would result in large 
carbon savings and can be achieved alongside reduced 
drug costs by using less expensive brands. Substantial 
carbon savings can be made by using small volume 
HFA134a MDIs, in preference to large volume HFA134a 
MDIs, or those containing HFA227ea as a propellant.
IntrODuCtIOn
Metered- dose inhalers (MDIs) contain propel-
lants, which are liquefied, compressed gases 
used as a driving force and an energy source 
for atomisation of the drug. Chlorofluoro-
carbons (CFCs), which were used originally, 
are both potent greenhouse gases (GHGs) 
and ozone- depleting substances, and were 
banned under the Montreal Protocol. They 
have been replaced by two hydrofluoroalkane 
(HFA) propellants; 1,1,1,2- tetrafluoroethane 
(HFA134a) and 1,1,1,2,3,3,3- heptafluoro
propane (HFA227ea).1 Currently, MDIs 
contribute an estimated 3.9% of the carbon 
footprint of the National Health Service 
(NHS) in the UK, because HFAs are potent 
GHGs.2 The UK has a high proportion of MDI 
use (70%) compared with <50% in the rest of 
Europe, and only about 10% in Scandinavia.3 
The most commonly used MDIs in the UK 
contain salbutamol reliever, although there 
is pressure to reduce excessive reliever use, 
which has been linked with poor outcomes in 
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Combating climate change has been described as ‘the 
greatest public health opportunity of the 21st century’.5 
HFAs are used mainly as refrigerants and are controlled 
under national F- gas regulations, and the Kigali Amend-
ment to the Montreal Protocol. As F- gas use is phased out, 
HFA MDIs will become a significant proportion of overall 
HFA use, especially in the UK, because of the high level 
of use of MDIs.
There have been calls to switch away from HFA MDIs 
because of their environmental impact.6 Effective HFA- 
free alternatives are already available, as DPIs and 
aqueous mist inhalers. Switching to inhalers with lower 
global warming potential (GWP) is a key part of the NHS 
Sustainable Development Unit’s strategy.7 In 2017, the 
British Thoracic Society recommended that prescribers 
and patients ‘consider switching pMDIs to non- propellant 
devices whenever they are likely to be equally effective’.8 
In May 2018, the UK’s Environmental Audit Committee 
recommended the NHS set a target of reducing to 50% 
low GWP inhalers by 2022.9 In January 2019, the NHS 
long- term plan proposed a 50% reduction in the GHG 
emissions from inhalers in 10 years,10 and established 
an expert working group to evaluate potential strategies 
to achieve this.11 There is patchy information about the 
carbon footprint of inhalers. Life- cycle analysis of salbu-
tamol MDIs has shown that 95%–98% of its carbon foot-
print derives from the use- phase, when the propellant is 
released and this dwarfs manufacturing processes.12–14 
This article collates and analyses information on type and 
volume of emitted propellant.
A significant barrier to switching away from MDIs might 
be the higher ‘up- front’ price of some DPIs; however, the 
price of MDIs does not take into account the long- term 
financial cost of their environmental impact. We inves-
tigate a variety of scenarios for altered inhaler prescrip-




We used 2017 prescription data from NHS digital website, 
including the number of inhalers prescribed and net 
ingredient cost.15 We separated inhalers into different 
categories: short- acting beta- agonists (SABAs), inhaled 
corticosteroids (ICS), long- acting beta- agonists (LABAs), 
short- acting muscarinic antagonists (SAMAs), long- 
acting muscarinic antagonists (LAMAs) and combination 
devices. Within these categories, we identified high GWP 
inhalers which contain HFA propellant, and low GWP 
inhalers which were DPIs and Respimat devices. The least 
expensive low GWP inhaler in each inhaler category was 
identified, and the cost and carbon impact of changing 
inhalers determined in various scenarios. Some discon-
tinued inhalers and those prescribed in very low numbers 
(<500 a year) were excluded from the analysis.
In model 1, we replaced MDIs with DPIs in the same 
proportions that brands of DPIs had been prescribed in 
England 2017, which we called ‘proportional replace-
ment’. For example, if three DPI inhalers (A, B and C) 
made up 50%, 30% and 20% of the DPIs in that cate-
gory, then proportional replacement would switch 50% of 
the MDIs to DPI inhaler A, 30% to B and 20% to C. The 
number of MDIs declines and DPIs increases, while the 
proportions of each DPI used stays the same.
In model 2, we replaced MDIs with the cheapest avail-
able equivalent DPI. We modelled several alternative 
scenarios described in table 1 and the paragraphs below 
on SABA and LABA/ICS combination inhalers.
SABA; salbutamol: in 2017, the least expensive MDI 
salbutamol was £1.88 versus the least expensive DPI salbu-
tamol Salbulin Novolizer at £3.36 for 200- dose inhaler. 
However, the Salbulin Novolizer is rarely used in the UK, 
with only 1015 prescriptions in 2017, so we modelled an 
alternative scenario in which we changed MDIs to Salbu-
tamol Easyhaler instead (£3.85 per inhaler).
LABA: the least expensive LABA in 2017 was Formoterol 
Easyhaler, which is similarly priced to the least expensive 
MDI LABA at £25.37 per inhaler.
ICS: we divided ICS inhalers as described in BTS/SIGN 
guidance into very low, low, medium and high strength 
inhalers.4 We identified the least expensive equivalent 
DPI ICS in each category. These were Flixotide 50 Accu-
haler (£8.54 per inhaler) one inhalation twice a day for 
very low strength, beclometasone 200 Easyhaler (£16.85 
per inhaler) one inhalation twice a day for low strength 
and two inhalations twice a day for medium strength, 
budesonide 400 Easyhaler (£20.39 per inhaler) two inha-
lations twice a day for high strength.
LABA/ICS combination inhalers: we divided inhalers 
into low, medium and high strength inhaled corticoste-
roids. The least expensive DPI inhalers were Seretide 
100 Accuhaler (£23.89 per inhaler), Relvar 92/22 Ellipta 
(£25.31per inhaler) and Fostair 200/6 Nexthaler (£33.28 
per inhaler), respectively. Relvar is a once- daily inhaler 
which would result in a change in dosing regimen for 
many patients, and it is also not licensed for maintenance 
and reliever therapy in patients with asthma. We therefore 
modelled an alternative scenario whereby we switched 
medium strength LABA/ICS combination inhalers to 
Fostair 100/6 Nexthaler (£33.42 per inhaler).
SAMA/LAMA and LAMA/LABA combination inhalers: we 
did not change these inhalers in our model as all SAMAs 
are MDI and all LAMAs and LAMA+LABA devices are 
DPI or aqueous mist inhalers. There are potential clin-
ical and environmental benefits from switching SAMA to 
LAMA inhalers.16
LABA/LAMA/ICS inhalers: two of these ‘triple’ inhalers 
became available for the first time in 2017, one MDI 
(Trimbow at £47.42) and one DPI (Trelegy at £58.10 per 
inhaler).
Greenhouse gas analysis
Information on the amount of HFA propellant in MDIs is 
not publicly available, so alternative sources of informa-
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Table 1 Financial implications of switching from MDIs to DPIs





Total cost of this 
type of inhaler (£)
Cheapest DPI 
alternative








SABA (salbutamol MDI) 21 930 625 58 195 683.24 Salbutamol 100 
Easyhaler
3 068 201.99 3 042 770.28
LABA (salmeterol 25 MDI) 700 145 25 250 958.95 Formoterol 
Easyhaler
1 474 723.02 −1 018 957.21
Very low dose ICS (Clenil 
modulite 50)
887 342 3 814 625.02 Flixotide Accuhaler 
50, one inhalation 
twice a day
875 534.13 875 534.13
Low dose ICS (Clenil 
modulite 100)
3 874 077 36 581 577.50 Beclometasone 
Easyhaler 200, one 
inhalation twice a 
day
2 461 791.16 −213 579.26
Medium dose ICS (Clenil 
modulite 200)
1 683 466 34 611 159.90 Beclometasone 
Easyhaler 200, two 
inhalations twice a 
day
3 828 332.15 −628 752.90
High dose ICS (Clenil 
modulite 250)
287 604 7 923 785.74 Budesonide 
Easyhaler 400, two 
inhalations twice a 
day
1 084 787.73 173 464.97
Low dose ICS+LABA 
(Seretide 50 Evohaler)
1 181 941 32 582 876.16 Duoresp Spiromax 
160/4.5, one 
inhalation twice a 
day
749 613.82 121 485.45
Medium dose ICS+LABA 
(Fostair 100/6 MDI)
9 467 562 373 045 012.90 Relvar Ellipta 92/, 
one inhalation once 
a day
3 124 173.89 −4 876 327.15
OR Fostair 100/6 
Nexthaler two 
inhalations twice a 
day
OR −1 123 070.10
High dose ICS+LABA 
(Seretide 250 Evohaler)
3 425 542 184 212 379.80 Fostair 200/6 
Nexthaler two 
inhalations twice a 
day
−4 541 648.60 −5 248 427.76
ICS+LAMA+LABA 
(Trimbow)
5211 247 464.50 Trelegy Ellipta 552 801.25 552 801.25
DPI, dry powder inhaler; ICS, inhaled corticosteroid; LABA, long- acting beta- agonist; LAMA, long- acting muscarinic antagonist; MDI, 
metered- dose inhalers ; SABA, short- acting beta- agonist.
MDIs by weighing empty and full inhalers, and patents also 
provide some data. The carbon footprint was estimated by 
multiplying the estimated weight of HFA propellant by its 
GWP. GWP is a measure of how much heat a GHG traps 
in the atmosphere over a specific time, relative to carbon 
dioxide. For the purposes of this article, we used GWP 
values of HFAs for a 100- year time horizon as reported in 
the Intergovernmental Panel on Climate Change (IPCC) 
Fifth Assessment Report.17
We identified the 20 most commonly prescribed MDIs 
using NHS prescribing data.18 We searched google 
patents search engine (https:// patents. google. com/) 
using the search terms ‘inhaler name’ or ‘drug name’ 
and HFA or HFA134a or HFA227ea. Links and citations 
from relevant results were followed. We also reviewed data 
from the Montreal Protocol Medical Technical Options 
Committee.19
The carbon footprint of commonly prescribed inhalers 
is summarised in table 2. All salbutamol MDIs use 
HFA134a, with a GWP of 1300. There are two types of 
salbutamol MDIs, one a small volume MDI containing 
alcohol as a co- solvent, which requires less HFA propel-
lant than the large volume alcohol- free type.20 A study 
comparing a large volume inhaler Ventolin Evohaler 
with small volume Salamol inhaler found the weight of 
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Table 2 Indicative carbon footprint of commonly prescribed MDIs by inhaler class

















of inhaler (g CO2e) 
























17.32–19.8 1300 22 520–28 000
(25 260)
200 112–129 Inhaler performance 





11 1300 14.3 kg (total product 
carbon footprint 
14.59 kg)
200 71.5 Product carbon 




12 1300 15 600–19 000
(17 300)
120 130 Patent,50 independent 
study23
ICS (eg, Clenil) 11.32–20 1300 14 700–26 000
(20 350)





12–18.2 1300 15 600–23 700
(19 650)






11 3320 36 500 120 295 Patent27
HFA, hydrofluoroalkane; HFA134a, 1,1,1,2- tetrafluoroethane; HFA227ea, 1,1,1,2,3,3,3- heptafluoropropane; ICS, inhaled corticosteroid; LABA, 
long- acting beta- agonist; MDI, metered- dose inhaler; SABA, short- acting beta- agonist; SAMA, short- acting muscarinic antagonist.
and 7.88 g, respectively. A GlaxoSmithKline (GSK) patent 
for salbutamol MDI shows inhalers containing 18.2 g 
and 19.8 g of HFA134a.21 22 GSK published a Carbon 
Trust- certified carbon footprint analysis which estimated 
Ventolin to have a carbon footprint of 28 kg CO2e/inhaler, 
far greater than a small volume inhaler (Proventil) at 
around 10 kgCO2e/inhaler.
12 23
For SAMAs, we used manufacturer’s product carbon 
footprint data on Atrovent which has a product carbon 
footprint of 14.59 kg.14
For ICS, comparison of two patents for beclometasone 
inhalers, suggest that those with alcohol use around half 
the HFA134a propellant (12.3 g with alcohol vs 20 g of 
HFA134a alone) of HFA134a.24 25
For LABA/ICS combination inhalers, one patent for 
fluticasone/salmeterol MDI (Seretide) contained 18.2 g 
of HFA134a.21 GSK published carbon footprint estimates 
19 kg CO2e/inhaler for their LABA, ICS/LABA and 
LABA MDIs. However, an FDA report on the US Advair 
brand of fluticasone/salmeterol MDI stated the inhaler 
has a net weight of just 12 g/inhaler.26
Two LABA/ICS MDIs (Symbicort MDI and Flutiform) 
use HFA227ea as a propellant, which has higher GWP 
of 3320. A patent for Flutiform indicates it contains 11 g 
(±0.5 g) of HFA227ea, resulting in the largest carbon foot-
print of any inhaler at 36.5 kg CO2e/inhaler.
27
Currently, both LAMA alone, and LAMA/LABA combi-
nations are exclusively available in the UK as DPIs. There 
is only one triple ICS/LAMA/LABA combination avail-
able in an MDI, and no data on propellant volume could 
be found (Trimbow).
DPIs and aqueous mist inhalers
DPIs and aqueous mist inhalers (such as Respimat) do not 
contain HFAs. The Medical Technical Options Committee 
of the United Nations estimated the carbon footprint of 
a DPI to be between 1.5 and 6 kg CO2e for a 200- dose 
inhaler (7.5–30g/dose) but most DPIs contain far fewer 
than 200 doses.19 GSK’s Carbon Trust- verified analysis 
of their DPIs (containing 1 months’ treatment) found a 
carbon footprint of slightly <1 kg CO2e/inhaler.
23 Product 
carbon footprint analysis of Spiriva Respimat published 
by the manufacturers found it to have a carbon footprint 
of 780 g CO2e, but potentially lower if refill cartridges are 
used.14 For our analyses we assumed a carbon footprint of 
1 kg CO2e per DPI, and used the midpoint of the range of 
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Patient and public involvement
A prior survey conducted in Hertfordshire, UK by one of 
the authors (AW) found that 86% of patients agreed that 
both cost and carbon footprint are important factors to 
consider when changing inhalers, although ease of use 
was considered the most important factor overall.28
reSultS
Financial implications
By analysing NHS prescription data, we modelled how 
prescription costs would change in various different 
prescription scenarios. In model 1, we replaced MDIs 
with DPIs in the same proportions that brands of DPIs 
had been prescribed in England 2017, which we called 
‘proportional replacement’. In this scenario, for every 
10% of MDIs changed the total cost increased by £12.7M 
annually. In model 2, we replaced MDIs with the cheapest 
available equivalent DPI. In this scenario, for every 10% 
of MDIs changed total cost decreased by £8.2M annually, 
but we saw different price changes for different types of 
inhalers.
SABA; salbutamol: when salbutamol MDIs were replaced 
with Salbulin Novolizer costs rose £2.02M for every 10% 
of MDIs changed. As Salbulin Novolizer is rarely used in 
the UK, we modelled an alternative scenario in which we 
changed MDIs to Salbutamol Easyhaler, whereby costs 
rose £3.01M for every 10% of inhalers changed.
LABA: when switching to Formoterol Easyhaler savings 
of £1.02M were made for every 10% of MDIs changed. 
For proportional replacement, costs increased by £1.47M 
for every 10% of MDIs changed.
ICS: we found costs increased slightly; £207K for every 
10% of MDIs switched to the cheapest DPI. For propor-
tional replacement costs rose £8.25M for every 10% of 
MDIs changed.
LABA/ICS combination inhalers: we saw large cost savings; 
£10.0M saved for every 10% of MDIs switched to the least 
expensive DPI LABA/ICS. When switching to Fostair 
100/6 Nexthaler instead of Relvar 92/22 Ellipta, as Fostair 
also has a license for maintenance and reliever therapy, 
we saw more modest cost savings of £6.25M for every 10% 
of MDIs switched. For ‘proportional’ replacement costs 
fell £668K for every 10% of MDIs changed.
LABA/ LAMA/ICS inhalers: in 2017, only 5211 of these 
inhalers were prescribed and the cost of switching from 
MDI to DPI was £555K for every 10% of inhalers switched.
Carbon footprint
We found some reliever inhalers (eg, Ventolin) to have 
a carbon footprint over 25 kg CO2e per inhaler, while 
others use far less HFA134a (eg, Salamol) with a carbon 
footprint of <10 kg CO2e per inhaler. HFA227ea LABA/
ICS inhalers (eg, Flutiform) have a carbon footprint 
over 36 kg CO2e, compared with an equivalent HFA134a 
combination inhaler (eg, Fostair) at <20 kg CO2e.We esti-
mated the total carbon footprint of MDIs prescribed in 
the community in England in 2017 to be 635 kt CO2e. For 
every 10% of HFA MDIs changed to low GWP devices 58 
kt CO2e could be saved annually. Reaching the Environ-
mental Audit Committee target of 50% of inhalers being 
low GWP devices by 2022, would save 288 kt CO2e every 
year. Reducing the proportion of high GWP devices to 
10%, as seen in Sweden, would result in carbon savings 
519 kt CO2e every year.
DISCuSSIOn
If prescribers switch from high GWP to the least expensive 
low GWP options within each therapeutic category, major 
financial savings could be made alongside large carbon 
reductions. Most of the savings are seen by switching 
from more expensive LABA/ICS MDIs to less expensive 
DPIs. These potential savings would exceed the cost of 
switching the larger volume of salbutamol MDIs to DPIs, 
because the incremental cost per salbutamol inhaler 
(<£2/inhaler) is much lower.
A second option in which prescribers switch from MDI 
to the DPIs according to the current proportions of brand 
prescribing, would be more expensive. Neither clinicians 
nor formularies would likely support a switch to equiva-
lent inhalers which were more expensive. A third option 
in which prescribers switch from an MDI to DPI for the 
same branded LABA/ICS combination (eg, Seretide or 
Fostair) is generally either cost neutral or less expensive.
There is recent focus on cost- effectiveness, which takes 
into account ease of use, dose frequency and other ‘softer’ 
factors that would encourage adherence, impact clinical 
outcomes and in turn economic cost in the real world. 
Poor inhaler technique is very common and greatly limits 
the effectiveness of inhaled medications. The most recent 
large meta- analysis identified fewer errors overall with 
DPIs, even when MDI users had spacers.29 The Salford lung 
study was a large, pragmatic randomised trial that showed 
improved clinical outcomes in patients with asthma and 
chronic obstructive pulmonary disease assigned to once- 
daily Relvar DPI instead of their usual inhaler (which was 
an MDI in 68%).30 31 One historical matched cohort study 
found better asthma control in patients initiated on an 
MDI compared with DPI, but this study only compared 
Seretide Evohaler and Accuhaler.32 A similar matched 
cohort study demonstrated patients with asthma can be 
switched from other ICS inhalers to the Easyhaler with 
no reduction in clinical effectiveness or change in cost.33 
Another similar study found better asthma control and 
fewer exacerbations in patients starting or increasing 
strength of DPIs or breath- actuated inhalers compared 
with pMDIs.34 A further benefit of DPIs is that they use a 
dose counter, whereas salbutamol and ICS MDIs generally 
do not. Patients often cannot determine when their MDIs 
are empty and either throw away half full inhalers, or 
conversely continue to use empty inhalers unknowingly.35
Our cost analysis has a number of limitations. Our 
data only includes community prescriptions in England; 
hospital prescriptions are not included. However, patients 
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Table 3 Strategies to reduce greenhouse gas emissions from MDIs
Strategy Effect Potential CO2e saving
Where appropriate, switch from MDI to 
non- propellant inhaler
Avoids use of HFA propellants. 8–36 kg per inhaler.
Change from large volume reliever 
(eg, Ventolin Evohaler) to small volume 
reliever (eg, Salamol)
Small volume reliever contains far less 
propellant.
18 kg per inhaler.
Change from HFA227ea inhaler (eg, 
Flutiform or Symbicort MDI) to HFA134a 
inhaler
Uses lower GWP HFA propellant. 20 kg CO2e per inhaler.
Recycle used MDIs The plastics and aluminium are recycled 
and the HFA gas is captured for re- use.
Estimated 4–18 kg per inhaler, although 
potentially risks further atmospheric release 
of HFA by delaying incineration.
Return used inhalers to pharmacy after 
use
If the pharmacy cannot recycle the 
MDI, it will be incinerated. This causes 
thermal degradation of the HFA into 
chemicals with far smaller global 
warming potential.38
Likely to be slightly lower than recycling 
due to the energy inputs for incineration, 
and the absence of recycled materials. 
Estimated 3–17 kg per inhaler.
If there is no dose counter, ensure your 
patient knows how many doses the 
inhaler contains
Reduce waste from disposing of half- 
used inhalers.
Estimated to be a quarter of the inhaler’s 
carbon footprint; roughly 4 kg CO2e per 
inhaler.
GWP, global warming potential; HFA, hydrofluoroalkane; HFA134a, 1,1,1,2- tetrafluoroethane; HFA227ea, 1,1,1,2,3,3,3- heptafluoropropane; 
MDI, metered- dose inhaler.
more severe disease requiring combination inhalers, 
so the potential cost savings could be even greater. Our 
models do not include the impact of future changes in 
prescribing practice such as the recent introduction of 
triple LAMA/LABA/ICS inhalers. In reality, costs are 
in flux and subject to market pressures, but our analysis 
allows comparison between treatments at a specific time 
point.
The MDIs assessed were found to have a wide range 
of carbon footprints; 10–37 times that of a DPI. The 
UK government reports incorrectly assumes that all 
inhalers contain 12 g of propellant.36 Even among MDIs, 
those containing HFA227ea propellant or large volume 
HFA134a propellant have twice the carbon footprint 
or more compared with small volume MDIs. At least 
6.5 million large volume MDIs for salbutamol were 
prescribed in England in 2016, and switching these to 
small volume MDIs could save 118 kt CO2e in England 
alone, with little clinical or patient impact.37 Our findings 
provide a potentially more accurate model that could be 
transferred to other countries wanting to monitor and 
regulate MDIs in relation to carbon footprint.
Inhaler recycling has the potential to reduce the envi-
ronmental impact of inhalers through recovery of propel-
lant, although so far uptake has been very low with <1% 
of MDIs recovered and of little measurable impact in 
climate terms.13 Where recycling is not available, inciner-
ating MDIs with medicines waste is an effective strategy; 
this causes thermal degradation of the HFA into chemi-
cals with far smaller global warming potential.38 A study 
of inhalers returned for recycling jointly funded by GSK 
and NHS Grampian showed that 48% of doses remain in 
MDIs, compared with just 27% in DPIs.39 This highlights 
the importance of explaining to patients the number of 
doses their inhaler contains as part of inhaler technique 
training. This also means that a significant proportion of 
the propellant could be captured, and that the carbon 
footprint of MDIs potentially roughly halved if they were 
all recycled and the HFA propellant reused. At the end 
of their useful life HFA must be incinerated however, and 
it is possible that recycling HFAs could provide further 
opportunities for atmospheric release by delaying incin-
eration. Other strategies to reduce GHG emissions from 
MDIs are summarised in table 3.
An important question is whether to switch to DPIs 
now, or wait for reformulated MDIs with novel low GWP 
propellants. Three low GWP propellants have been 
considered, isobutane, HFA152a and HFO 1234ea. An 
isobutane programme has been underway for a decade 
in Argentina, but not yet been commercialised. HFA152a 
has a lower carbon footprint (one- tenth of HFA134a) and 
HFO1234ea zero, but both remain at early stage develop-
ment.1 Very large clinical trials will be required to estab-
lish their safety, alone and then in combination with every 
moiety that uses them. Transition to a novel propellant(s) 
would likely take at least a decade based on experience 
from the transition from CFCs,40 although this may be 
cost- effective from a worldwide perspective, especially in 
low- income and middle- incomedeveloping countries.
Several papers assert that some patients are unable to 
generate the inspiratory flows necessary to activate DPIs, 
particularly during exacerbations.41 42 However, 93% of 
prescriptions for LAMA or LAMA/LABA devices for COPD 
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vast majority of patients can use a DPI effectively.18 In 
contrast, 94% of SABA prescriptions are for MDIs leading 
to a confusing mixture of inhalation techniques.18 
Patients with COPD whose inhaler devices use the same 
inhalation technique show better clinical outcomes than 
those prescribed devices requiring different techniques.43 
One small study examined patients’ ability to use MDIs 
and DPIs effectively during the course of an exacerbation 
and found best results from an Accuhaler DPI which has 
medium resistance but is effective at relatively low peak 
inspiratory flow rates of 30 L/min.44 Switching to DPI 
SABAs could potentially lead to a simplification of inhala-
tion technique, an improvement in care and a reduction 
in carbon footprint. A recent proposal suggests a reliever 
MDI+spacer could be kept separately in an emergency 
pack in case of exacerbations.45 Whatever inhalers are 
used, adequate patient training and assessment of inhaler 
technique will be essential for efficient and effective 
inhaler use.29
Patients care about the carbon footprint of their 
inhalers. One survey of inhaler users found that 78% 
rated carbon footprint as important; equally important 
to them as financial cost.28 Changing one MDI device 
to a DPI could save 150–400 kg CO2e annually; roughly 
equivalent to installing wall insulation at home, recycling 
or cutting out meat.46 These are individual actions that 
many environmentally concerned individuals are keen to 
take.
Our carbon footprint results for England are consistent 
with other studies of MDIs in the UK (which included 
Scotland, Wales and Northern Ireland), which show that 
they contribute approximately a megaton of CO2e to 
global GHG emissions. Climate change is estimated to kill 
250 000 people annually by 2030, particularly vulnerable 
people in financially poor countries.47 Physicians should 
not shy away from these issues, and tools, such as NICE’s 
recent patient decision aid for asthma inhalers are to be 
welcomed.48
COnCluSIOnS
Climate change is a huge and present threat to health 
which will disproportionately impact the poorest and 
most vulnerable on the planet, including people with 
pre- existing lung disease. Every effort must be made to 
minimise GHG release to protect current and future 
generations from the worst effects of climate change.
Switching to low GWP inhalers can be achieved while 
making financial savings in terms of drug costs. Patients, 
prescribers and guideline authors should carefully 
consider the carbon footprint of these inhalers and where 
they are likely to be equally effective, prioritise low GWP 
inhalers.
Where MDIs are considered necessary, other steps can 
be taken immediately to reduce their environmental 
impact. Smaller volume HFA134a inhalers should be 
prioritised over larger volume or HFA227ea- containing 
inhalers, manufacturers should consider phasing out the 
use of HFA227ea and patients, manufacturers and clini-
cians should publicise and encourage inhaler recycling.
twitter Alexander J K Wilkinson @DrAlexWilkinson
Acknowledgements The authors would like to thank Professor Ashley Woodcock 
of Manchester University for comments and help refining the manuscript.
Contributors All authors meet the required criteria for authorship. AJKW: helped 
design the study, collected and analysed the data and wrote the manuscript. 
RB: helped design the study, collected and analysed the data and revised the 
manuscript. IS: helped analyse the data and revise the manuscript. JS: helped 
design the study, collected and analysed the data and revised the manuscript.
Funding The authors have not declared a specific grant for this research from any 
funding agency in the public, commercial or not- for- profit sectors.
Competing interests JS reports personal fees from Trumpington Street Medical 
Practice, grants and personal fees from NHS England, personal fees from World 
Health Organization Europe, Better Value Healthcare, Cambridgeshire County 
Council, University of Cambridge, outside the submitted work; and he is married to 
a practising general practitioner in Cambridgeshire.
Patient consent for publication Not required.
Provenance and peer review Not commissioned; externally peer reviewed.
Data availability statement Data are available on reasonable request.
Open access This is an open access article distributed in accordance with the 
Creative Commons Attribution Non Commercial (CC BY- NC 4.0) license, which 
permits others to distribute, remix, adapt, build upon this work non- commercially, 
and license their derivative works on different terms, provided the original work is 
properly cited, appropriate credit is given, any changes made indicated, and the use 
is non- commercial. See: http:// creativecommons. org/ licenses/ by- nc/ 4. 0/.
Author note All authors meet the required criteria for authorship: substantial 
contributions to the conception or design of the work; the acquisition, analysis 
or interpretation of data for the work; drafting the work or revising it critically for 
important intellectual content; final approval of the version to be published and 
agreement to be accountable for all aspects of the work in ensuring that questions 
related to the accuracy or integrity of any part of the work are appropriately 
investigated and resolved.
OrCID iD
Alexander J K Wilkinson http:// orcid. org/ 0000- 0002- 1808- 3663
reFerenCeS
 1 Myrdal PB, Sheth P, Stein SW. Advances in metered dose inhaler 
technology: formulation development. AAPS PharmSciTech 
2014;15:434–55.
 2 NHS Sustainable Development Unit. Reducing the use of natural 
resources in health and social care. 2018 Report, 2018: 1–31.
 3 Lavorini F, Corrigan CJ, Barnes PJ, et al. Retail sales of inhalation 
devices in European countries: so much for a global policy. Respir 
Med 2011;105:1099–103.
 4 BTS/SIGN British guideline for the management of asthma, SIGN 
153, 2016. Available: http://www. sign. ac. uk/ sign- 153- british- 
guideline- on- the- management- of- asthma. html
 5 Wang H, Horton R. Tackling climate change: the greatest opportunity 
for global health. Lancet 2015.
 6 Hillman T, Mortimer F, Hopkinson NS. Inhaled drugs and global 
warming: time to shift to dry powder inhalers. BMJ 2013;346.
 7 NHS Sustainable Development Unit. Sustainable development in the 
health and care system: health check 2016. 16, 2016.
 8 British Thoracic Society. The environment and lung health position 
statement, 2017. Available: https://www. brit- thoracic. org. uk/ 
document- library/ audit- and- quality- improvement/ environment- and- 
lung- health/ the- environment- and- lung- health/
 9 Creagh M, Labour MP, Clark C. Conservative MP. Environmental 
audit Committee UK progress on reducing F- gas emissions, 2018.
 10 The NHS long term plan. London, 2019. Available: www. 
longtermplan. nhs. uk
 11 Centre for Sustainable Healthcare. Expert Working Group on 
reducing the climate change impact of inhalers, 2018. Available: 
https:// networks. sust aina bleh ealt hcare. org. uk/ networks/ sustainable- 
respiratory- care/ expert- working- group- reducing- climate- change- 



















pen: first published as 10.1136/bm





8 Wilkinson AJK, et al. BMJ Open 2019;9:e028763. doi:10.1136/bmjopen-2018-028763
Open access 
 12 Goulet B, Olson L, Mayer B. A comparative life cycle assessment 
between a metered dose inhaler and electric nebulizer. Sustainability 
2017;9:1725.
 13 GSK. Complete the cycle – how we’re recycling inhalers, 2018. 
Available: https://www. gsk. com/ en- gb/ behind- the- science/ how- 
we- do- business/ complete- the- cycle- how- we- re- recycling- inhalers/ 
[Accessed 18 Jul 2018].
 14 Hänsel M, Bambach T, Wachtel H. Reduced environmental impact of 
a reusable soft mist inhaler. Eur Respir J 2018;52:PA1021.
 15 NHS England. NHS digital, 2017. Available: https:// digital. nhs. uk/ 
prescribing [Accessed 17 Jul 2018].
 16 Cheyne L, Irvin- Sellers MJ, White J, et al. Tiotropium versus 
ipratropium bromide for chronic obstructive pulmonary disease. 
Cochrane Database Syst Rev 2015;23.
 17 Global warming potential values, 2014. Available: https://www. 
ghgprotocol. org/ sites/ default/ files/ ghgp/ Global- Warming- Potential- 
Values %28Feb 16  2016% 29_ 1. pdf [Accessed 17 Jan 2019].
 18 NHS Business Services Authority. Available: https://www. nhsbsa. 
nhs. uk/ sites/ default/ files/ 2017- 10/ PCA Aug  17. xlsx %0A [Accessed 
21 Aug 2018].
 19 Montreal protocol on substances that deplete the ozone layer report 
of the UNEP medical technical options Committee 2014 assessment. 
Nairobi, Kenya, 2014.
 20 Sellers WFS. Asthma pressurised metered dose inhaler performance: 
Propellant effect studies in delivery systems. Allergy Asthma Clin 
Immunol 2017;13.
 21 Akehurst RA, Taylor AJ, Wyatt DA. Aerosol formulations containing 
Propellant 134a and fluticasone propionate, 1997. Available: https://
www. google. com/ patents/ US5658549
 22 Ian I, Ashurst C, Herman CS, et al. United States Patent (19) 2000.
 23 Atherton M. Environmental impact of inhalers, 2017. Available: 
https://www. greatermanchester- ca. gov. uk/ download/ meetings/ id/ 
2423/ environmental_ impact_ of_ inhalers [Accessed 27 Aug 2018].
 24 Brambilla G, Johnson R, Lewis DA. Aerosol inhalation device, 2014. 
Available: https://www. google. com/ patents/ WO2014033057A1? cl= 
en
 25 Brown M, Jones S, Martin G. Metered dose inhalation preparations 
of therapeutic drugs, 2010. Available: https:// patents. google. com/ 
patent/ WO2005055985A1/ en? q= qvar+ AND+ HFA134& oq= qvar+ 
AND+ HFA134 [Accessed 17 Aug 2018].
 26 (DMETS) D of ME and TS. Center for drug evaluation and research 
application number: NDA 21-254, 2006. Available: https://www. 
accessdata. fda. gov/ drugsatfda_ docs/ nda/ 2006/ 021254s000_ 
NameR. pdf
 27 Mueller- Walz R, Fueg LM. Medicinal aerosol  
formulations, 2014. Available: https://www. google. com/ patents/ 
US20140314684
 28 Liew KL, Wilkinson A. P280 How do we choose inhalers? patient and 
physician perspectives on environmental, financial and ease- of- use 
factors. Thorax 2017;72:A235–7.
 29 Sanchis J, Gich I, Pedersen S, et al. Systematic review of errors 
in inhaler use: has patient technique improved over time? Chest 
2016;150:394–406.
 30 Woodcock A, Vestbo J, Bakerly ND, et al. Effectiveness of fluticasone 
furoate plus vilanterol on asthma control in clinical practice: an 
open- label, parallel group, randomised controlled trial. Lancet 
2017;390:2247–55.
 31 Vestbo J, Leather D, Diar Bakerly N, et al. Effectiveness of fluticasone 
Furoate- Vilanterol for COPD in clinical practice. N Engl J Med 
2016;375:1253–60.
 32 Price D, Roche N, Christian Virchow J, et al. Device type and real- 
world effectiveness of asthma combination therapy: an observational 
study. Respir Med 2011;105:1457–66.
 33 Price DB, Rigazio A, Buatti Small M, et al. Historical cohort study 
examining comparative effectiveness of albuterol inhalers with and 
without integrated dose counter for patients with asthma or chronic 
obstructive pulmonary disease. J Asthma Allergy 2016;9:145–54.
 34 Price D, Haughney J, Sims E, et al. Effectiveness of inhaler types for 
real- world asthma management: retrospective observational study 
using the GPRD. J Asthma Allergy 2011;4:37–47.
 35 Conner JB, Buck PO. Improving asthma management: the case for 
mandatory inclusion of dose counters on all rescue bronchodilators. 
J Asthma 2013;50:658–63.
 36 Webb N, Broomfield M, Brown P, et al. UK greenhouse gas inventory, 
1990 to 2012: annual report for submission under the framework 
convention on climate change, 2014. Available: https:// assets. 
publishing. service. gov. uk/ government/ uploads/ system/ uploads/ 
attachment_ data/ file/ 573172/ UKna tion alin vent oryr epor t1990- 2014. 
pdf% 0Ahttp:// nora. nerc. ac. uk/ 508171/
 37 Williamson IJ, Reid A, Monie RD, et al. Generic inhaled salbutamol 
versus branded salbutamol. A randomised double- blind study. 
Postgrad Med J 1997;73:156–8.
 38 Waste and Resources Action Programme. Inhalers | recycle now. 
Available: https://www. recyclenow. com/ what- to- do- with/ inhalers-0 
[Accessed 20 May 2019].
 39 NHS Grampian audit. Available: www. dontwasteabreath. com/ view/ 
facts [Accessed 5 Mar 2018].
 40 Woodcock A. The president speaks: prevention is best: lessons from 
protecting the ozone layer. Thorax 2012;67:1028–31.
 41 Al- Showair RAM, Tarsin WY, Assi KH, et al. Can all patients with 
COPD use the correct inhalation flow with all inhalers and does 
training help? Respir Med 2007;101:2395–401.
 42 Adachi Y, Adachi YS, Itazawa T. Measurement of peak inspiratory 
flow rates with an in- check meter to identify preschool children's 
ability to use dry powder inhalers; Diskus and Turbuhaler. J Allergy 
Clin Immunol 2004;113.
 43 Bosnic- Anticevich S, Chrystyn H, Costello RW, et al. The use of 
multiple respiratory inhalers requiring different inhalation techniques 
has an adverse effect on COPD outcomes. Int J Chron Obstruct 
Pulmon Dis 2017;12:59–71.
 44 Broeders MEAC, Molema J, Hop WCJ, et al. The course of inhalation 
profiles during an exacerbation of obstructive lung disease. Respir 
Med 2004;98:1173–9.
 45 Keeley D, Partridge MR. Emergency MDI and spacer packs for 
asthma and COPD. Lancet Respir Med 2019;7:380–2.
 46 Wynes S, Nicholas KA. The climate mitigation gap: education and 
government recommendations miss the most effective individual 
actions. Environ Res Lett 2017;12:074024–9.
 47 Climate change and health. World Health Organization, 2018. 
Available: http://www. who. int/ en/ news- room/ fact- sheets/ detail/ 
climate- change- and- health
 48 Excellence NI for H and C. Patient decision aid. Inhalers for asthma. 
London, 2019.
 49 Thompson J. A process for the production and screening of materials 
for use in pharmaceutical aerosol formulations, 2017. Available: 
https:// patents. google. com/ patent/ EP1588698A2/ [Accessed 4 Aug 
2018].
 50 Godfrey A, Warby RB. Metered dose inhaler for salmeterol xinafoate, 




















pen: first published as 10.1136/bm
jopen-2018-028763 on 29 O
ctober 2019. D
ow
nloaded from
 
